Healthcare provider profile · identity verified

Larry Joe Edwards, DPM

Podiatry · YAKIMA, WA · NPI 1952402802

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	482	182
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	426	69
Lisinopril	Lisinopril	348	123
Amlodipine Besylate	Amlodipine Besylate	309	105
Albuterol Sulfate Hfa	Albuterol Sulfate	274	100
Tamsulosin Hcl	Tamsulosin Hcl	234	82
Levothyroxine Sodium	Levothyroxine Sodium	222	66
Losartan Potassium	Losartan Potassium	198	76
Ibuprofen	Ibuprofen	174	80
Gabapentin	Gabapentin	171	59
Pantoprazole Sodium	Pantoprazole Sodium	164	49
Hydrochlorothiazide	Hydrochlorothiazide	150	56
Famotidine	Famotidine	131	38
Trazodone Hcl	Trazodone Hcl	131	41
Fluticasone Propionate	Fluticasone Propionate	129	54
Baclofen	Baclofen	124	23
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	121	13
Omeprazole	Omeprazole	115	34
Furosemide	Furosemide	111	38
Tramadol Hcl	Tramadol Hcl	108	13
Tizanidine Hcl	Tizanidine Hcl	102	18
Metoprolol Tartrate	Metoprolol Tartrate	101	40
Simvastatin	Simvastatin	100	37
Metoprolol Succinate	Metoprolol Succinate	96	33
Atenolol	Atenolol	94	35
Montelukast Sodium	Montelukast Sodium	91	27
Potassium Chloride	Potassium Chloride	88	23
Meloxicam	Meloxicam	87	21
Alvesco	Ciclesonide	81	26
Sertraline Hcl	Sertraline Hcl	76	18
Terazosin Hcl	Terazosin Hcl	76	21
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	74	69
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	72	24
Metformin Hcl Er	Metformin Hcl	71	26
Metformin Hcl	Metformin Hcl	66	27
Naproxen	Naproxen	63	14
Allopurinol	Allopurinol	62	23
Alendronate Sodium	Alendronate Sodium	57	18
Glipizide	Glipizide	57	22
Spiriva Respimat	Tiotropium Bromide	56	15
Lovastatin	Lovastatin	55	20
Wixela Inhub	Fluticasone Propion/Salmeterol	53	28
Hydrocortisone	Hydrocortisone	52	16
Acetaminophen-Codeine	Acetaminophen With Codeine	51	suppressed
Hydralazine Hcl	Hydralazine Hcl	51	21
Clopidogrel	Clopidogrel Bisulfate	49	16
Finasteride	Finasteride	49	17
Hydroxyzine Hcl	Hydroxyzine Hcl	48	17
Carvedilol	Carvedilol	46	20
Triamcinolone Acetonide	Triamcinolone Acetonide	46	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	16
Rosuvastatin Calcium	Rosuvastatin Calcium	43	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	42	36
Azithromycin	Azithromycin	42	40
Humulin N	Insulin Nph Human Isophane	41	17
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	41	16
Clonidine Hcl	Clonidine Hcl	40	suppressed
Methocarbamol	Methocarbamol	40	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	40	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	37	11
Doxycycline Monohydrate	Doxycycline Monohydrate	35	23
Sumatriptan Succinate	Sumatriptan Succinate	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	13
Ondansetron Hcl	Ondansetron Hcl	33	suppressed
Ondansetron Odt	Ondansetron	33	17
Prednisone	Prednisone	33	23
Lorazepam	Lorazepam	32	14
Acyclovir	Acyclovir	31	suppressed
Nabumetone	Nabumetone	31	suppressed
Butalbital-Aspirin-Caffeine	Butalbital/Aspirin/Caffeine	30	suppressed
Spironolactone	Spironolactone	29	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	28	20
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	25	17
Colchicine	Colchicine	25	11
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	25	13
Clobetasol Propionate	Clobetasol Propionate	24	12
Benazepril Hcl	Benazepril Hcl	23	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Breyna	Budesonide/Formoterol Fumarate	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	21	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	21	suppressed
Cephalexin	Cephalexin	20	19
Ezetimibe	Ezetimibe	20	suppressed
Ozempic	Semaglutide	20	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Amoxicillin	Amoxicillin	18	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Bupropion Hcl	Bupropion Hcl	17	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Chlorthalidone	Chlorthalidone	14	suppressed
Fluocinonide	Fluocinonide	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Glipizide Er	Glipizide	12	suppressed
Cosentyx Sensoready (2 Pens)	Secukinumab	11	suppressed
Digoxin	Digoxin	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Otezla	Apremilast	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error